Individuals living with pre-existing heart disease who received a shingles vaccine demonstrated a significantly reduced rate of serious heart-related events within a year, nearly half that of their unvaccinated counterparts. This groundbreaking discovery, poised for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26), adds substantial weight to the growing body of evidence suggesting broader protective benefits of the herpes zoster vaccine beyond its primary role in preventing shingles. The research, drawing from a vast dataset of over 246,822 adults across the United States previously diagnosed with atherosclerotic heart disease—a condition characterized by the dangerous accumulation of plaque in the arteries—underscores a potential paradigm shift in preventive cardiology. The findings not only reinforce the vaccine’s efficacy against shingles but also hint at its capacity to mitigate risks associated with severe cardiovascular conditions and potentially even neurodegenerative disorders like dementia. Unprecedented Cardioprotective Effects in High-Risk Populations Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the lead author of the study, emphasized the cumulative nature of these findings. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke, and death," Dr. Nguyen stated. He further highlighted the amplified benefit observed in the study’s cohort: "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This observation is particularly salient given the substantial global burden of cardiovascular disease, which remains the leading cause of death worldwide. According to the World Health Organization, an estimated 17.9 million people die each year from cardiovascular diseases, representing 32% of all global deaths. In the United States, approximately 695,000 people die from heart disease each year, making it the leading cause of death for most demographic groups. Any intervention that can significantly reduce adverse events in this vulnerable population holds immense public health implications. The Mechanism: How Shingles Infection Impacts Cardiovascular Health The Centers for Disease Control and Prevention (CDC) universally recommends the shingles vaccine for all adults aged 50 years and older, along with younger individuals who have compromised immune systems. The vaccine targets herpes zoster, the medical term for shingles, a condition characterized by a painful, blistering rash. This debilitating rash can sometimes progress to postherpetic neuralgia (PHN), a long-lasting and severe nerve pain that can persist for months or even years after the rash has healed. Shingles itself is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox, which lies dormant in nerve cells for decades after the initial childhood infection. As individuals age or their immune systems weaken, VZV can reactivate, leading to shingles. Approximately one in three people in the U.S. will develop shingles during their lifetime. The hypothesized link between shingles and cardiovascular events centers on the inflammatory response triggered by the viral infection. Earlier investigations have established that a shingles episode can induce systemic inflammation and endothelial dysfunction, leading to the formation of dangerous blood clots near vital organs, including the brain and heart. This inflammatory cascade significantly elevates the risk of acute cardiovascular events such as heart attacks, ischemic strokes, and venous thromboembolism (VTE). By preventing the initial shingles infection, the vaccine is believed to interrupt this inflammatory pathway, thereby diminishing the likelihood of these subsequent and often life-threatening clotting events. The shingles vaccine, specifically the recombinant zoster vaccine (RZV) known as Shingrix, has demonstrated over 90% efficacy in preventing shingles and PHN in adults 50 years and older, far surpassing the efficacy of its predecessor, Zostavax. Rigorous Study Design and Striking Risk Reductions To execute this comprehensive study, researchers leveraged TriNetX, an extensive electronic health records database encompassing de-identified medical data from millions of Americans. The cohort under examination included adults aged 50 years or older diagnosed with atherosclerotic disease, with data spanning from 2018 to 2025. The analysis meticulously compared 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine with an equal number of unvaccinated individuals. Crucially, both groups were carefully matched on demographic characteristics, pre-existing health conditions, and socioeconomic factors (including housing, economic circumstances, social environment, employment status, education, and literacy) to minimize confounding variables and ensure a robust comparison. The primary focus of the research was on heart-related outcomes that occurred between one month and one year following vaccination (or within the equivalent timeframe for the unvaccinated control group). The results were compelling and consistent across all measured outcomes: Major Adverse Cardiac Events (MACE): Vaccinated individuals were a remarkable 46% less likely to experience a MACE, a composite endpoint often including heart attack, stroke, and cardiovascular death. All-Cause Mortality: The risk of death from any cause was reduced by a striking 66% in the vaccinated group. Heart Attack (Myocardial Infarction): The likelihood of experiencing a heart attack dropped by 32%. Stroke: The risk of stroke was lowered by 25%. Heart Failure: Vaccinated patients showed a 25% reduction in the incidence of heart failure. Dr. Nguyen underscored the magnitude of these reductions, comparing them favorably to the established health benefits of significant lifestyle changes, such as quitting smoking. "These reductions are substantial and comparable to the benefits seen from quitting smoking," he noted, adding that "the findings reinforce current recommendations for adults over age 50 to receive the vaccine." The implications for public health are profound, offering a relatively simple yet highly effective intervention for a population already at elevated cardiovascular risk. Broader Context: The Evolving Understanding of Vaccines as Preventive Tools The study’s findings contribute to a burgeoning field of research exploring the "non-specific effects" of vaccines—benefits that extend beyond the prevention of the target pathogen. While often associated with childhood immunizations, evidence is mounting for similar broader protections in adult vaccines. This study’s reinforcement of the shingles vaccine’s cardioprotective effects underscores the multifaceted value of immunization programs. From a public health perspective, the message is clear and compelling. "Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. He acknowledged the challenges posed by misinformation in the current climate: "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." Health organizations, including the American Heart Association and the CDC, consistently advocate for evidence-based preventive measures. While formal statements directly reacting to this specific study are pending its full presentation, these bodies are likely to integrate such findings into their broader messaging on preventive care, emphasizing the importance of vaccination as a component of comprehensive health management for cardiovascular patients. Limitations, Future Research, and Long-Term Impact Despite its robust methodology and significant findings, the study, like all research, possesses certain limitations. The analysis primarily tracked outcomes within the first year following vaccination, meaning the long-term protective effects require further investigation. However, this limitation is partially addressed by prior research. A previous study, published in 2025, indicated that shingles vaccination was associated with a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially enduring for up to eight years. This suggests that the observed protective effects may not be transient and could offer sustained cardiovascular benefits. Another inherent challenge in observational studies is the potential for confounding factors, specifically "healthy user bias." Individuals who proactively choose to get vaccinated may also be more likely to engage in other health-promoting behaviors, such as regular exercise, a balanced diet, and adherence to medical advice. While the researchers meticulously adjusted for numerous health and socioeconomic factors, it remains a possibility that some portion of the observed benefit could be influenced by these unmeasured differences in health-seeking behaviors. Even with this consideration, the study’s immense sample size and sophisticated statistical adjustments provide compelling evidence that shingles vaccination is independently and significantly associated with a meaningful reduction in heart-related risks. Future research will undoubtedly focus on elucidating the precise biological mechanisms underlying this cardioprotection, potentially through biomarker studies measuring inflammatory markers, coagulation factors, and endothelial function. Longer-term follow-up studies are also crucial to ascertain the durability of these protective effects and to identify any specific patient subgroups who might benefit most from vaccination. The economic impact of such a widespread preventive measure—reducing hospitalizations, costly interventions, and rehabilitation for cardiovascular events—also warrants detailed analysis. The presentation of this pivotal study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," is scheduled for Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E, at the American College of Cardiology’s Annual Scientific Session. Its implications are far-reaching, offering a powerful new argument for broader vaccine uptake and potentially reshaping clinical guidelines for cardiovascular disease prevention. Post navigation This reengineered HPV vaccine trains T cells to hunt down cancer
